4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶盐酸盐 | 1187830-90-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶盐酸盐
• 英文名称: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine dihydrochloride
• 英文别名: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine hydrochloride；4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine;hydrochloride
• CAS: 1187830-90-5
• 化学式: C₆H₉N₃*2ClH
• 分子量: 196.079
• InChiKey: MGEFXKKDBHBPEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.48
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.7
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,5,6,7-四氢-1H-吡唑并[3,4-C]吡啶盐酸盐 、 4-氯-6,7-二甲氧基喹唑啉 在 四丁基碘化铵 N,N-二异丙基乙胺 作用下， 以 异丁酰胺 为溶剂， 反应 6.08h， 以40%的产率得到6,7-dimethoxy-4-(1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)quinazoline
  参考文献：
  名称：

  WO2007/22280

  摘要：

  公开号：

文献信息

• [EN] PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDO[5,4-D]PYRIMIDINE SERVANT D'INHIBITEURS D'ENT POUR LE TRAITEMENT DE CANCERS, ET LEUR COMBINAISON AVEC DES ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：ITEOS BELGIUM SA

  公开号：WO2021170797A1

  公开（公告）日：2021-09-02

  The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula (I), including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

  本发明涉及式(I)的嘧啶并[5,4-d]嘧啶衍生物，包括其药用可接受盐和溶剂化合物。本发明的化合物是ENT家族转运蛋白的抑制剂，特别是ENT1的抑制剂，并且可用作治疗癌症的治疗化合物。该发明还涉及将嘧啶并[5,4-d]嘧啶衍生物与腺苷受体拮抗剂联合使用，用于治疗癌症。
• [EN] CINNOLINE DERIVATIVES AS AS BTK INHIBITORS<br/>[FR] DÉRIVÉS DE CINNOLINE EN TANT QU'EN TANT QU'INHIBITEURS DE LA BTK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013148603A1

  公开（公告）日：2013-10-03

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

  公开的是Formula 1的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在规范中有定义。这些化合物是Bruton酪氨酸激酶（BTK）的抑制剂。本公开还涉及制备Formula 1化合物的材料和方法，包括含有它们的药物组合物，以及它们用于治疗与BTK相关的疾病、疾病或症状的用途。
• T-TYPE CALCIUM CHANNEL BLOCKER
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP3053917A1

  公开（公告）日：2016-08-10

  It is an object to provid a novel compound that has an excellent T-type calcium channel inhibitory activity and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. The present invention provides a novel triazinone compound of Formula (I): where each substituent in the formula is defined in detail in the description, and R1 means a hydrogen atom, or a C1-6 alkyl group, etc., E means a 7 to 14-membered non-aromatic fused heterocyclic group, L3 means a C1-6 alkylene group, etc., D means a C6-14 aryyl group or a 5 to 10-membered heteroaryl group each of which is optionally substituted, etc., a tautomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

  本发明提供一种新颖的化合物，具有优异的T型钙通道抑制活性，特别适用于预防或治疗疼痛、慢性肾脏疾病和心房颤动。该新颖的三氮杂酮化合物的化学式如下（I）：其中公式中的每个取代基在描述中有详细定义，R1表示氢原子，或者C1-6烷基等，E表示一个由非芳香性融合杂环组成的7到14成员环，L3表示C1-6烷基链等，D表示一个C6-14芳基或者一个5到10成员杂环基，每个基都可以选择性取代等，化合物的互变异构体，或其药学上可接受的盐，或其溶剂化合物。
• 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships
  作者：David N. Deaton、Curt D. Haffner、Brad R. Henke、Michael R. Jeune、Barry G. Shearer、Eugene L. Stewart、J. Darren Stuart、John C. Ulrich

  DOI：10.1016/j.bmc.2018.03.021

  日期：2018.5

  Starting from 4-amino-8-quinoline carboxamide lead 1a and scaffold hopping to the chemically more tractable quinazoline, a systematic exploration of the 2-substituents of the quinazoline ring, utilizing structure activity relationships and conformational constraint, resulted in the identification of 39 novel CD38 inhibitors. Eight of these analogs were 10-100-fold more potent human CD38 inhibitors, including the single digit nanomolar inhibitor 1am. Several of these molecules also exhibited improved therapeutic indices relative to hERG activity. A representative analog 1r exhibited suitable pharmacokinetic parameters for in vivo animal studies, including moderate clearance and good oral bioavailability. These inhibitor compounds will aid in the exploration of the enzymatic functions of CD38, as well as furthering the study of the therapeutic implications of NAD enhancement in metabolic disease models. (C) 2018 Elsevier Ltd. All rights reserved.
• TW2016/7941
  申请人：——

  公开号：——

  公开（公告）日：——